MYC and lymphoma: Further studies utilizing CG-806 in combination with venetoclax show inhibition of driver and rescue pathways within in-vivo studies using double/triple hit lymphoma cell lines that harbor MYC/BCL2/BCL6 mutations, yielding promising results [51].